Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows

v3.20.4
Condensed Consolidated Statements of Cash Flows - USD ($)
3 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Cash flows from operating activities:    
Net loss $ (4,066,431) $ (4,505,550)
Adjustments to reconcile net loss to net cash used in operating activities    
Stock-based compensation 1,176,585 1,504,226
Change in fair value of warrant liabilities (630,112) 694,134
Depreciation and amortization 68,117 149,746
Loss on disposal of fixed asset 0 3,230
Equity in losses on equity method investment 25,412 24,509
Loss on marketable securities 14,970 0
Changes in operating assets and liabilities    
Prepaid insurance, other expenses and current assets (25,132) (86,880)
Long-term prepaid insurance 48,417 48,417
Security Deposit (253,565) 0
Accounts payable (327,087) (110,641)
Accrued expenses and other current liabilities 187,965 (162,677)
Net cash used in operating activities (3,780,861) (2,441,486)
Cash flows from investing activities    
Purchase of laboratory and office equipment (193,571) (68,400)
Purchase of marketable securities (15,003,771) 0
Sale of marketable securities 14,988,801 0
Net cash used in investing activities (208,541) (68,400)
Cash flows from financing activities    
Principal payment of financed insurance (138,557) (73,426)
Proceeds from exercise of stock options 112,446 0
Net cash used in financing activities (26,111) (73,426)
Net decrease in cash and cash equivalents (4,015,513) (2,583,312)
Cash and cash equivalents, beginning of period 31,992,283 10,313,966
Cash and cash equivalents, end of period 27,976,770 7,730,654
Supplemental disclosure of cash flow information:    
Cash paid for interest 10,400 1,326
Cash paid for income taxes $ 0 $ 0